Acasti Pharma Inc
XTSX:ACST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Acasti Pharma Inc
XTSX:ACST
|
CA |
|
Japan Creative Platform Group Co Ltd
TSE:7814
|
JP |
|
Eclerx Services Ltd
NSE:ECLERX
|
IN |
|
China Strategic Holdings Ltd
HKEX:235
|
HK |
|
Keppel REIT
SGX:K71U
|
SG |
|
Nitto Boseki Co Ltd
TSE:3110
|
JP |
|
A
|
ATN Holdings Inc
XPHS:ATN
|
PH |
|
UNO Minda Ltd
NSE:UNOMINDA
|
IN |
|
Third Coast Bancshares Inc
NASDAQ:TCBX
|
US |
|
G
|
Grupa Zywiec SA
WSE:ZWC
|
PL |
|
Shahlon Silk Industries Ltd
BSE:542862
|
IN |
|
FirstEnergy Corp
NYSE:FE
|
US |
|
S
|
Seera Holding Group SJSC
SAU:1810
|
SA |
|
R
|
Rise Inc
TSE:8836
|
JP |
|
Galaxy Bearings Ltd
BSE:526073
|
IN |
|
P
|
Panchmahal Steel Ltd
BSE:513511
|
IN |
|
KDA Group Inc
XTSX:KDA
|
CA |
|
Toppan Forms Co Ltd
TSE:7862
|
JP |
|
T
|
Tien Len Steel Corporation JSC
VN:TLH
|
VN |
|
Z
|
Zhongjing Food Co Ltd
SZSE:300908
|
CN |
|
Tianneng Power International Ltd
HKEX:819
|
CN |
|
AGP Corp
TSE:9377
|
JP |
|
Rede Energia Participacoes SA
BOVESPA:REDE3
|
BR |
|
VL E-Governance & IT Solutions Ltd
NSE:VLEGOV
|
IN |
Acasti Pharma Inc
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The firm is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The firm's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The firm's other pipeline products include GTX-102, an oral mucosal spray formulation of betamethasone intended to develop neurological symptoms of A-T, including developing clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. GTX-101 is a topical bio-adhesive film-forming spray of bupivacaine for the treatment of PHN.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
